Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel and Iniparib in Breast cancer, run by Sanofi, completed.
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients is a phase 2 interventional study registered as NCT01204125 by Sanofi, with 141 participants recorded, started 2010-09 and reaching its primary completion in 2012-10. Interventions recorded: paclitaxel, Iniparib (SAR2405550 -BSI-201). Conditions recorded: Breast Cancer Female.
Linked to the drug Iniparib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iniparib, Sanofi, Breast cancer (all types) and the tag pipeline.
Shares Iniparib, Sanofi, Breast cancer (all types) and the tag pipeline.
Shares Sanofi, Breast cancer (all types) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/